AngioScore, Inc. was founded in 2003 with the mission of developing, making and selling leading edge tools for endovascular therapy. The company’s senior management team has built and led successful companies in interventional cardiology, cardiac surgery and diabetes treatment. Our Medical Advisory Board is made up of thought leaders in interventional cardiology practice and research.

The AngioSculpt Scoring Balloon Catheter is AngioScore’s first product. There were 2.2 million coronary angioplasty procedures worldwide in 2004 representing an estimated $855 million in sales of balloon angioplasty catheters.

The AngioSculpt scoring balloon catheter is CE mark approved for routine use in coronary arteries as an alternative to traditional angioplasty balloons. Traditional balloon angioplasty catheters have evolved little over the past 15 years ago and have many limitations. The innovative design of the AngioSculpt Scoring Balloon Catheter and its superb clinical performance provides interventional cardiologists with a long-needed improvement over traditional angioplasty balloons, particularly in patients with complex lesions.

Page